TNF-a Preconditioning Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in an Experimental Model of Atherosclerosis

Atherosclerosis (AS) is an inflammatory disease involving multiple factors in its initiation and development. In recent years, the potential application of mesenchymal stem cells (MSCs) for treating AS has been investigated. This study examined the effect of TNF-a preconditioning on MSCs' therapeutic efficacy in treating AS in ApoE KO mice. TNF-a-treated MSCs were administered to high-fat diet-treated ApoE KO mice. Cytokine and serum lipid levels were measured before and after treatment. Cryosections of the atherosclerotic aorta were stained with Oil-Red-O, and the relative areas of atherosclerotic lesions were measured. The level of Tregs were increased in TNF-a-MSC-treated animals compared to the MSCs group. In addition, the systemic administration of TNF-a-MSCs to ApoE KO mice reduced the level of proinflammatory cytokines such as TNF-a and IFN-? and increased the level of the immunosuppressive IL-10 in the blood serum. Total cholesterol and LDL levels were decreased, and HDL levels were increased in the TNF-a-MSCs group of ApoE KO mice. A histological analysis showed that TNF-a-MSCs decreased the size of the atherosclerotic lesion in the aorta of ApoE KO mice by 38%, although there was no significant difference when compared with untreated MSCs. Thus, our data demonstrate that TNF-a-MSCs are more effective at treating AS than untreated MSCs.

Automated summary

This study found that TNF-a preconditioning of mesenchymal stem cells (MSCs) is more effective in treating atherosclerosis (AS) than untreated MSCs. TNF-a-MSCs reduced the size of atherosclerotic lesions, decreased proinflammatory cytokine levels, increased immunosuppressive factor levels, and regulated serum lipid levels.